Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women

PLoS One. 2012;7(11):e49296. doi: 10.1371/journal.pone.0049296. Epub 2012 Nov 21.

Abstract

Background: Somatic alterations of cyclin-dependent kinase 2 (CDK2)-cyclin E complex have been shown to contribute to breast cancer (BC) development and progression. This study aimed to explore the effects of single nucleotide polymorphisms (SNPs) in CDK2 and CCNE1 (a gene encoding G1/S specific cyclin E1 protein, formerly called cyclin E) on BC risk, progression and survival in a Chinese Han population.

Methodology/principal findings: We herein genotyped 6 haplotype-tagging SNPs (htSNPs) of CCNE1 and 2 htSNPs of CDK2 in 1207 BC cases and 1207 age-matched controls among Chinese Han women, and then reconstructed haplotype blocks according to our genotyping data and linkage disequilibrium status of these htSNPs. For CCNE1, the minor allele homozygotes of three htSNPs were associated with BC risk (rs3218035: adjusted odds ratio [aOR] = 3.35, 95% confidence interval [CI] = 1.69-6.67; rs3218038: aOR = 1.81, 95% CI = 1.22-2.70; rs3218042: aOR = 2.64, 95% CI = 1.31-5.34), and these three loci showed a dose-dependent manner in increasing BC risk (P(trend) = 0.0001). Moreover, the 5-SNP haplotype CCGTC, which carried none of minor alleles of the 3 at-risk SNPs, was associated with a favorable event-free survival (hazard ratio [HR] = 0.53, 95% CI = 0.32-0.90). Stratified analysis suggested that the minor-allele homozygote carriers of rs3218038 had a worse event-free survival among patients with aggressive tumours (in tumour size>2 cm group: HR = 2.06, 95% CI = 1.06-3.99; in positive lymph node metastasis group: HR = 2.41, 95% CI = 1.15-5.03; in stage II-IV group: HR = 2.03, 95% CI = 1.09-3.79). For CDK2, no significant association was found.

Conclusions/significance: This study indicates that genetic variants in CCNE1 may contribute to BC risk and survival in Chinese Han population. They may become molecular markers for individual evaluation of BC susceptibility and prognosis. Nevertheless, further validation studies are needed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asian People / genetics*
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / pathology
  • Case-Control Studies
  • China
  • Cyclin E / genetics*
  • Cyclin-Dependent Kinase 2 / genetics*
  • Disease Progression
  • Ethnicity / genetics
  • Female
  • Gene Frequency / genetics
  • Genetic Association Studies
  • Genetic Predisposition to Disease*
  • Germ Cells / metabolism*
  • Haplotypes / genetics
  • Humans
  • Kaplan-Meier Estimate
  • Linkage Disequilibrium / genetics
  • Middle Aged
  • Neoplasm Staging
  • Oncogene Proteins / genetics*
  • Polymorphism, Single Nucleotide / genetics*
  • Proportional Hazards Models
  • Risk Factors

Substances

  • CCNE1 protein, human
  • Cyclin E
  • Oncogene Proteins
  • CDK2 protein, human
  • Cyclin-Dependent Kinase 2

Grants and funding

This study was supported by the National Natural Science Foundation of China (Grant Nos 81171961 and 30670805), the Key Project of the Chinese Ministry of Education (Grant No. 108003) and the Beijing Municipal Education Commission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.